Shareholding disclosure

Armistice Capital Master Fund Ltd

Declared position

19.66%

Threshold

Crossed upwards

Timeline

Published

19.09.2023

Transaction

01.09.2023

Voting rights breakdown

Voting rights acquired19.66%

Voting rights sold0%

Below threshold0%

Notice details

CategorySingle shareholder

ExchangeXSWX

Notification ID

TAN9I00027

Beneficial owner

Armistice Capital Master Fund Ltd

Declared address

Armistice Capital Master Fund Ltd, New York, NY

Open shareholder profile Open company profile

Back to the feed

Shareholding disclosure

Armistice Capital Master Fund Ltd

MindMaze Therapeutics Holding SA19.09.2023TAN9I00027

Disclosure summary

Armistice Capital Master Fund Ltd disclosed a holding in MindMaze Therapeutics Holding SA on the acquisition side, published by SIX Exchange Regulation on 19.09.2023, at 19.66% of voting rights. Notice category: Single shareholder.

Disclosed position

19.66%

Voting rights acquired

Voting rights acquired19.66%

Voting rights sold0%

Below threshold0%

Never miss a market signal again

Create a free account

Need more? Discover the Pro plan

Pro alertsEmail and Telegram after publication

Unlimited company trackingUnlimited watchlist with the Pro plan

Monday recapYour stocks' essentials at the open

Disclosure detail

Armistice Capital Master Fund Ltd disclosed a holding in MindMaze Therapeutics Holding SA, published on 19.09.2023.

Publication date19.09.2023

Transaction date01.09.2023

Issuing companyMindMaze Therapeutics Holding SA

Beneficial ownerArmistice Capital Master Fund Ltd

Declared addressArmistice Capital Master Fund Ltd, New York, NY

CategorySingle shareholder

Voting rights acquired19.66%

Voting rights sold0%

Below threshold0%

ExchangeXSWX

Notification IDTAN9I00027

Source: SIX Exchange Regulation · Publication date: 19.09.2023

These figures aggregate public disclosures. They are not investment advice.

insider24.ch

Never miss a market signal again

Create a free account

Need more? Discover the Pro plan

Pro alertsEmail and Telegram after publication

Unlimited company trackingUnlimited watchlist with the Pro plan

Monday recapYour stocks' essentials at the open